{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:20:53Z","timestamp":1791980453417,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lungcan.2025.108598","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:28:26Z","timestamp":1748892506000},"page":"108598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Lurbinectedin for extensive stage \u2212 small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes"],"prefix":"10.1016","volume":"205","author":[{"given":"Belal","family":"Krayim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Shalata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3646","authenticated-orcid":false,"given":"Jair","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Moskovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7821-9625","authenticated-orcid":false,"given":"Ofer","family":"Rotem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas Gantz","family":"Sorotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Kian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Hanovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranin","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shir","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afifi","family":"Basel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleb","family":"Kornev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1720-069X","authenticated-orcid":false,"given":"Noam","family":"Asna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Peled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila C.","family":"Roisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2025.108598_b0005","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108598_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"23","key":"10.1016\/j.lungcan.2025.108598_b0015","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2025.108598_b0020","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lungcan.2025.108598_b0025","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/cncr.25526","article-title":"Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer","volume":"117","author":"Foster","year":"2011","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2025.108598_b0030","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical Practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108598_b0035","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108598_b0040","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2025.108598_b0045","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/imj.16348","article-title":"Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme","volume":"54","author":"Alexander","year":"2024","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.lungcan.2025.108598_b0050","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s11523-023-00995-1","article-title":"Comparative effectiveness of lurbinectedin for the treatment of relapsed small cell lung cancer in the post-platinum setting: a real-world Canadian synthetic control arm analysis","volume":"18","author":"Boyne","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2025.108598_b0055","first-page":"149","article-title":"Real-world outcomes with lurbinectedin in second line and beyond for extensive stage small cell lung cancer in Korea","volume":"15","author":"Shim","year":"2024","journal-title":"Lung Cancer (Auckl)."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108598_b0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/1120009X.2024.2302736","article-title":"Review of real-world experience with lurbinectedin in relapsed\/refractory small cell lung cancer","volume":"36","author":"Wasifuddin","year":"2024","journal-title":"J. Chemother."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108598_b0065","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cllc.2023.09.001","article-title":"Real-world outcomes with lurbinectedin in second-line setting and beyond for extensive stage small cell lung cancer","volume":"24","author":"Desai","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2025.108598_b0070","article-title":"Lurbinectedin sensitizes PD-L1 blockade by activating STING\u2013IFN signaling in SCLC (preclinical)","volume":"5","author":"Chakraborty","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"25","key":"10.1016\/j.lungcan.2025.108598_b0075","first-page":"00064","article-title":"Lurbinectedin plus pembrolizumab in relapsed SCLC: phase I\/II LUPER study","volume":"S1556\u20130864","author":"Calles","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108598_b0080","unstructured":"Jazz Pharmaceuticals. Press Release (Oct 15, 2024): Phase 3 IMforte trial (lurbinectedin + atezolizumab) meets OS and PFS endpoints in ES-SCLC."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004908?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004908?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:49:43Z","timestamp":1752590983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"alternative-id":["S0169500225004908"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108598","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurbinectedin for extensive stage \u2212 small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108598"}}